U.S was Pfizer’s largest region in fiscal 2025, bringing in $74.16B of $125.16B (59%).
| Geography | FY 2009 | FY 2010 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S | $86.63B | $56.29B | $74.16B | |||||||||||
| Us | — | — | — | |||||||||||
| United States | — | — | — | |||||||||||
| United States [Member} | — | — | — | |||||||||||
| Developed Markets | $81.07B | $41.82B | $32.38B | |||||||||||
| Developed Europe | — | — | — | |||||||||||
| Emerging Markets | $34.65B | $21.00B | $18.63B | |||||||||||
| Developed Rest Of World | — | — | — | |||||||||||
| Total | $202.35B | $119.11B | $125.16B |
Pfizer brought in $125.16B from its three regions in fiscal 2025, the year ended December 31, 2025. That was up 5.1% from $119.11B in fiscal 2023, the previous year with figures. U.S was the largest at $74.16B (59.2%), ahead of Developed Markets at $32.38B (25.9%) and Emerging Markets at $18.63B (14.9%).
Compared with fiscal 2023, the previous year with figures, U.S grew fastest, up 31.7% to $74.16B, while Developed Markets fell the most, down 22.6% to $32.38B. From fiscal 2022 to 2025, combined revenue from these regions fell from $202.35B to $125.16B, a compound annual decline of 14.8%. U.S's share of the total rose from 42.8% to 59.2%.
Legacy Established Products was Pfizer’s largest segment in fiscal 2014, bringing in $26.03B of $50.69B (51%).
| Segment | FY 2014 |
|---|---|
| Legacy Established Products | $26.03B |
| Peri-Loe Products | $17.71B |
| Sterile Injectable Pharmaceuticals | $6.55B |
| Centreone | $396.00M |
| Total | $50.69B |
Pfizer brought in $50.69B from its four segments in fiscal 2014, the year ended December 31, 2014. Legacy Established Products was the largest at $26.03B (51.4%), ahead of Peri-Loe Products at $17.71B (34.9%) and Sterile Injectable Pharmaceuticals at $6.55B (12.9%). The remaining segment, Centreone, brought in $396.00M.
All Other Biopharmaceutical Products was Pfizer’s largest revenue line in fiscal 2013, bringing in $14.72B of $103.17B (14%).
| Products and Services | FY 2009 | FY 2010 | FY 2012 | FY 2013 |
|---|---|---|---|---|
| Lipitor | $21.47B | $7.90B | $4.63B | |
| All Other Biopharmaceutical Products | $16.24B | $15.61B | $14.72B | |
| Prevnar Family | — | $8.23B | $7.95B | |
| Lyrica | $6.13B | $8.32B | $9.19B | |
| Alliance Revenues | $8.17B | $6.98B | $5.26B | |
| Animal Health | $7.15B | — | — | |
| Enbrel (Outside The U.S. & Canada) | $6.55B | $7.47B | $7.55B | |
| Celebrex | $4.75B | $5.44B | $5.84B | |
| Consumer Healthcare | $5.50B | $6.42B | $6.68B | |
| Prevnar 13/ Prevenar 13 | $4.83B | — | — | |
| Viagra | $3.86B | $4.10B | $3.76B | |
| Norvasc | $3.01B | $2.70B | $2.46B | |
| Zyvox | $2.35B | $2.69B | $2.71B | |
| Xalatan / Xalacom | $3.50B | $1.61B | $1.18B | |
| Sutent | $2.13B | $2.47B | $2.41B | |
| Geodon / Zeldox | — | — | — | |
| Premarin Family | $2.08B | $2.15B | $2.18B | |
| Genotropin | $1.77B | $1.66B | $1.54B | |
| Vfend | $1.65B | $1.51B | $1.55B | |
| Detrol / Detrol La | $2.03B | $1.52B | $1.12B | |
| Effexor | $3.44B | $850.00M | $880.00M | |
| Prevnar / Prevenar (7-Valent) | $2.51B | — | — | |
| Chantix / Champix | $1.51B | $1.34B | $1.30B | |
| Benefix | $1.29B | $1.55B | $1.66B | |
| Refacto Af/ Xyntha | $808.00M | $1.17B | $1.20B | |
| Zoloft | $1.06B | $1.08B | $938.00M | |
| Zosyn / Tazocin | $1.90B | $968.00M | $790.00M | |
| Medrol | $910.00M | $1.05B | $928.00M | |
| Pristiq | $932.00M | $1.26B | $1.40B | |
| Revatio | $962.00M | $1.07B | $614.00M | |
| Zithromax / Zmax | $830.00M | $870.00M | $774.00M | |
| Caduet | $1.05B | $516.00M | $446.00M | |
| Cardura | $826.00M | $676.00M | $592.00M | |
| Pfizer Centresource | — | — | — | |
| Aricept | $908.00M | $652.00M | $470.00M | |
| Fragmin | $682.00M | $762.00M | $718.00M | |
| Relpax | $646.00M | $736.00M | $718.00M | |
| Xanax Xr | $614.00M | — | — | |
| Other | $638.00M | $462.00M | $728.00M | |
| Aromasin | — | $420.00M | $370.00M | |
| Rapamune | $776.00M | $692.00M | $700.00M | |
| Neurontin | $644.00M | $470.00M | $432.00M | |
| Xanax/Xanax Xr | — | $548.00M | $552.00M | |
| Geodon | — | $706.00M | $388.00M | |
| Arthrotec | — | — | — | |
| Tygacil | $648.00M | $670.00M | $716.00M | |
| Diflucan | $556.00M | $518.00M | $484.00M | |
| Sulperazon | $426.00M | $524.00M | $618.00M | |
| B M P 2 | — | $526.00M | $418.00M | |
| Bmp2 | $800.00M | — | — | |
| Unasyn | $488.00M | $456.00M | $424.00M | |
| Dalacin / Cleocin | $428.00M | — | — | |
| Inlyta | — | $200.00M | $638.00M | |
| Xalkori | — | $246.00M | $564.00M | |
| Nutrition | — | — | — | |
| Inspra | $314.00M | $428.00M | $466.00M | |
| Somavert | $314.00M | $394.00M | $434.00M | |
| Depo-Provera | — | $296.00M | $382.00M | |
| Toviaz | $274.00M | $414.00M | $472.00M | |
| Xeljanz | — | $12.00M | $228.00M | |
| Methotrexate | — | — | — | |
| Total | $130.33B | $109.31B | $103.17B |
Pfizer brought in $103.17B from its 50 revenue lines in fiscal 2013, the year ended December 31, 2013. That was down 5.6% from $109.31B in fiscal 2012. All Other Biopharmaceutical Products was the largest at $14.72B (14.3%), ahead of Lyrica at $9.19B (8.9%) and Prevnar Family at $7.95B (7.7%). The other 47 revenue lines brought in $71.31B combined.
Compared with fiscal 2012, Lyrica grew fastest, up 10.5% to $9.19B, while Lipitor fell the most, down 41.4% to $4.63B.
Pfizer began breaking out Prevnar Family in fiscal 2012, Xanax/Xanax Xr in fiscal 2012, Geodon in fiscal 2012 and B M P 2 in fiscal 2012. Pfizer stopped reporting Animal Health ($7.15B in fiscal 2010), Prevnar 13/ Prevenar 13 ($4.83B in fiscal 2010), Prevnar / Prevenar (7-Valent) ($2.51B in fiscal 2010) and three others as separate revenue lines.
Pfizer (PFE) reports its revenue by geography, by segment and by products and services. In fiscal 2025, U.S was its largest region, bringing in $74.16B (59.2% of the total), followed by Developed Markets at $32.38B (25.9%).
U.S was Pfizer's largest region in fiscal 2025, bringing in $74.16B, or 59.2% of the $125.16B total across its three regions.
Legacy Established Products was Pfizer's largest segment in fiscal 2014, bringing in $26.03B, or 51.4% of the $50.69B total across its four segments.
All Other Biopharmaceutical Products was Pfizer's largest revenue line in fiscal 2013, bringing in $14.72B, or 14.3% of the $103.17B total across its 50 revenue lines.
Among Pfizer's revenue lines that make up at least 2% of revenue, Lyrica grew fastest in fiscal 2013, up 10.5% from $8.32B to $9.19B.
Every figure comes from Pfizer's annual financial filings, as reported. Each line keeps the name Pfizer gives it, and years follow its fiscal calendar.
Pfizer's revenue by geography goes back to fiscal 2009, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.